Aptamer-mediated CRISPR base editing technology for precise single-nucleotide changes in vegetable crops. Achieves over 90% editing efficiency in mammalian cells and superior performance in plants compared to direct-fusion platforms. Enables multiplex editing without double-strand DNA breaks and with minimal off-target effects.
This offering combines a proprietary aptamer-mediated CRISPR base editing platform, known as Pin-point Base Editing, with deep expertise in plant gene editing to deliver precise single-base modifications in vegetable crops. Unlike conventional CRISPR-Cas9 approaches that rely on double-strand DNA breaks, this technology introduces targeted nucleotide changes directly, reducing the risk of unwanted genomic rearrangements and off-target mutations. The platform is designed for crop trait improvement applications where specific point mutations can deliver desired agronomic outcomes such as disease resistance, improved nutritional profile, or enhanced shelf life.
The technology has demonstrated over 90% base editing efficiency at target sites in mammalian cells, with multiplex editing at four simultaneous sites each exceeding 80% efficacy. In plants, the aptamer-mediated approach has shown superior performance compared to direct-fusion base editing platforms. The platform's therapeutic counterpart has been licensed to a major life sciences company and sublicensed for cell therapy applications, underscoring its commercial validation.
Key features:
Validation approach:
The Pin-point Base Editing platform has been extensively validated in mammalian systems, achieving over 90% base editing efficiency at target sites and demonstrating robust multiplex editing capabilities. The aptamer-mediated approach has also been validated in plant systems, including rice, where it outperformed direct-fusion base editing platforms. The technology has been licensed for therapeutic applications, providing additional commercial validation of its efficacy and reliability.
For vegetable crop applications, the platform is ready for translational development. The proposed workflow leverages established protocols for vector construction, component optimization in protoplast or callus, and plant regeneration through gene gun transformation. The two-laboratory collaboration combines proprietary base editing technology with specialized crop gene editing expertise, positioning the platform for successful delivery of gene-edited vegetable crops within a two to three year timeframe.
Rutgers University is a comprehensive public research university and New Jersey’s flagship, spanning campuses in New Brunswick–Piscataway, Newark, and Camden. For industry, it offers an integrated clinical and biomedical enterprise through its health system, a statewide extension network for field deployment, and campus-based incubators and pilot-scale facilities that enable prototyping and scale-up. Companies engage through sponsored research, shared core facilities, professional education, and flexible partnership models supported by corporate engagement teams. Research is supported by competitive federal funding from agencies such as NIH, NSF, DOE, and USDA. A dedicated technology transfer office manages IP, licensing, material transfer, and startup formation, providing clear pathways from lab discovery to market.